GERCOR (France)

Recent papers from GERCOR (France)

1. Nivolumab-Ipilimumab for Localized Microsatellite Instability–High Gastric/Gastroesophageal Junction AdenocarcinomaJAMA Oncology · 2026
2. Emergency integrative supportive care program for frail patients with advanced pancreatic cancer: A prospective GERCOR ARCAD study2026
3. Circulating tumour DNA in patients with colorectal cancer undergoing curative-intent LIver MEtastases Surgery in France: a prospective, multicentre GERCOR G-118 CLIMES PRODIGE 77 cohort study protocolBMJ Open · 2026
4. Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in patients with localized microsatellite instability-high (MSI)/mismatch repair deficient (dMMR) oeso-gastric adenocarcinoma: Long-term follow-up of the GERCOR NEONIPIGA phase II study.Journal of Clinical Oncology · 2026
5. STRATEGIC-1: multiple-line, randomized, open-label GERCOR-PRODIGE-39 phase III trial in unresectable RAS/BRAF wild-type metastatic colorectal cancerSignal Transduction and Targeted Therapy · 2026
6. Abstract 6209: Gynecologic carcinosarcomas beyond epithelial-mesenchymal transition: Morpho-transcriptomic evidence of an immune gradient in the tumor microenvironmentCancer Research · 2026
7. Response to: Correspondence on “Evaluation of the impact of NOAC underdosing and exploration of bleeding risk factors in elderly patients with atrial fibrillation: artificial intelligence-based approach” by Protzenko et alEuropean Journal of Hospital Pharmacy · 2026
8. Evaluation of the impact of NOAC underdosing and exploration of bleeding risk factors in elderly patients with atrial fibrillation: artificial intelligence-based approachEuropean Journal of Hospital Pharmacy · 2026
9. Neoadjuvant pembrolizumab with a watch‑and‑wait strategy for localized MSI/dMMR colon cancer: Study protocol for a randomized GERCOR 109 – PRODIGE 84 phase II trial (PREMICES)Digestive and Liver Disease · 2025
10. Management of biliary tract cancers in elderly patients: a French multicenter retrospective study (PRONOBIL-ACABi)Therapeutic Advances in Medical Oncology · 2025
11. Sunitinib as Second‐Line Treatment in Advanced Intrahepatic Cholangiocarcinoma: Results From the SUN ‐ CK GERCOR Phase II TrialLiver International · 2025
12. Medical management of pancreatic cancer: from personalization to broadening treatment strategiesCancer Treatment Reviews · 2025
13. Interplay between sarcopenia, GDF-15, and the efficacy of nivolumab plus ipilimumab in patients with mismatch repair deficient metastatic colorectal cancer: final survival analysis of the phase II GERCOR NIPICOL studyJournal for ImmunoTherapy of Cancer · 2025
14. Muscle Loss During First‐Line Chemotherapy Impairs Survival in Advanced Pancreatic Cancer Despite Adapted Physical ActivityJournal of Cachexia Sarcopenia and Muscle · 2025
15. The METACER national cohort study of brain metastases in gastrointestinal cancers prospectively establishes prognostic factorsJournal of Neuro-Oncology · 2025
16. Real-life data on biliary tract cancers in France: The nested Amber study from the French ACABi GERCOR PRONOBIL retro-prospective, observational cohortDigestive and Liver Disease · 2024
17. Optimization of intra-peritoneal chemotherapy: Randomized phase II GERCOR CHIMOVIP study.Journal of Clinical Oncology · 2024
18. Management of biliary tract cancers in early‐onset patients: A nested multicenter retrospective study of the ACABI GERCOR PRONOBIL cohortLiver International · 2024
19. Effect of Adapted Physical Activity in Patients With Advanced Pancreatic Cancer: The APACaP GERCOR Randomized TrialJournal of the National Comprehensive Cancer Network · 2023
20. Physical Activity as the Best Supportive Care in Cancer: The Clinician’s and the Researcher’s PerspectivesCancers · 2022